FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

OMB APPROVAL							
OMB Number:	3235-0287						
Estimated average burden							
hours per response:	0.5						

	Check this box if no longer subject to Section
	16. Form 4 or Form 5 obligations may continue
$\overline{}$	See Instruction 1(b).

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

Name and Address of Reporting Person* Temsamani Karim Saad					2. Issuer Name and Ticker or Trading Symbol Cardlytics, Inc. [CDLX]									onship of Repor all applicable) Director	ting Perso	on(s) to	10% Own	ner	
(Last) (First) (Middle) 675 PONCE DE LEON AVE. NE					3. Date of Earliest Transaction (Month/Day/Year) 07/01/2023							X	Officer (give below)		Other (specify below) cutive Officer		pecify below)		
SUITE 6000 (Street)				4.	4. If Amendment, Date of Original Filed (Month/Day/Year)								6. Individ	1					
ATLANTA	GA	30	308	_ R	Form filed by More than One Reporting Person Rule 10b5-1(c) Transaction Indication							5011							
(City)	(State)	(Zi	o)		Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.														
	Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned																		
			2. Transaction Date (Month/Day/Year)				Code (Instr. 8) (D) (Instr		rities Acquired (A) or Dispo tr. 3, 4 and 5)		Disposed Of	Beneficially Ow Following Repo		Form:	nership Direct (D) or ct (I) (Instr. 4)	7. Nature of Indirect Beneficial			
						(Month/	Day/Year)	Code	v	Amount		(A) or (D)	Price	e Transaction(s) (Instr. 3 and 4) Ownersi				Ownership (Instr. 4)	
Common Stock				07/0	1/2023		M		50,000(1)		A	\$0	50,000			D			
Common Stock				07/0	3/2023	23		S		25,574 ⁽²⁾		D	\$6.126 ⁽³⁾	24,426			D		
Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)																			
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisa Expiration Date (Month/Day/Yea		е	and 7. Title and Amount of S Underlying Derivative S (Instr. 3 and 4)			8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported	ve es ially ng	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)	
				Code	v	(A)	(D)	Date Exercis		Expiration Date	Title		Amount or Number of Shares		Transaci (Instr. 4)	tion(s)			
Restricted Stock Unit	(4)	07/01/2023		M			50,000	(5)		(5)	Com	non Stock	50,000	\$0	150,0	000	D		

Explanation of Responses:

- 1. Represents the underlying vested shares of common stock of the Issuer which have not been delivered.
- 2. Shares sold to satisfy withholding tax obligations upon the delivery of shares of common stock for restricted stock units ("RSUs") that vested on July 1, 2023.
- 3. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from \$5.98 to \$6.48 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon receipt, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
- 4. Each RSU represents a contingent right to receive one share of common stock of the Issuer, or at the election of the Issuer, its cash equivalent.
- 5. 25% of the RSUs shall vest on each of July 1, 2023, October 1, 2023, January 1, 2024 and April 1, 2024, respectively, subject to the Reporting Person's continuous service with the Issuer through each applicable vesting date.

Remarks:

/s/ Jason Minio, Attorney-in-Fact 07/05/2023 ** Signature of Reporting Person Date

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

- * If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
- ** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

POWER OF ATTORNEY

(For Executing Form ID and Forms 3, 4 and 5)

Know all by these presents, that the undersigned hereby constitutes and appoints Eric Jensen, Mark Ballantyne, Trey Reilly, William DuVal and Jason Minio of Cooley LLP, and Nick Lynton and Jamie Koo of Cardlytics, Inc. (the "Company"), signing individually, the undersigned's true and lawful attorneys-in fact and agents to:

- (1) Prepare, execute in the undersigned's name and on the undersigned's behalf, and submit to the the Securities and Exchange Commission (the "SEC") Form ID and Forms 3, 4 and 5 (including amendments thereto and joint filing agreements in connection therewith) in accordance with Section 16(a) of the Securities Exchange Act of 1934, as amended (the "Exchange Act") and the rules thereunder in the undersigned's capacity as an officer, director or beneficial owner of more than 10% of a registered class of securities of the Company;
- (2) Do and perform any and all acts for and on behalf of the undersigned that may be necessary or desirable to prepare and execute any such Form ID and Forms 3, 4 or 5 (including amendments thereto and joint filing agreements in connection therewith) and file such forms with the SEC and any stock exchange, self-regulatory association or any similar authority; and
- (3) Take any other action of any type whatsoever in connection with the foregoing that, in the opinion of such attorney-in-fact, may be of benefit to, in the best interest of, or legally required of the undersigned, it being understood that the documents executed by the attorney-in-fact on behalf of the undersigned pursuant to this Power of Attorney shall be in such form and shall contain such terms and conditions as the attorney-in-fact may approve in the attorney-in-fact's discretion.

The undersigned hereby grants to each such attorney-in-fact full power and authority to do and perform any and every act and thing whatsoever requisite, necessary, or proper to be done in the exercise of any of the rights and powers herein granted, as fully to all intents and purposes as the undersigned might or could do if personally present, with full power of substitution or revocation, hereby ratifying and confirming all that such attorney-in-fact, or such attorney-in-fact's substitute or substitutes, shall lawfully do or cause to be done by virtue of this power of attorney and the rights and powers herein granted. The undersigned acknowledges that the foregoing attorneys-in-fact, and their substitutes, in serving in such capacity at the request of the undersigned, are not assuming (nor is the Company assuming) any of the undersigned's responsibilities to comply with Section 16 of the Exchange Act.

This Power of Attorney shall remain in full force and effect until the earliest to occur of (a) the undersigned is no longer required to file Form ID or Forms 3, 4 and 5 with respect to the undersigned's holdings of and transactions in securities issued by the Company, (b) revocation by the undersigned in a signed writing delivered to the Company and the foregoing attorneys-in fact or (c) as to any attorney-in-fact individually, until such attorney-in-fact is no longer employed by the Company or Cooley LLP, as applicable.

IN WITNESS WHEREOF, the undersigned has caused this Power of Attorney to be executed as of the date written below.

Date: 6/13/2023 | 7:06 AM EDT

Karim Temsamani